The association of sEVs with the pathobiology of NAFLD indicates that sEVs are inflammatory drivers of NAFLD, and loading with key modulators, including CD9, CD63, and CD81, occurs in the setting of immune-mediated inflammation [75]. This evidence concerns the gene CD81 and metabolic dysfunction-associated steatotic liver disease.